Aromasin
Aromasin, known generically as exemestane, is an aromatase inhibitor used primarily in the treatment of hormone receptor–positive breast cancer in postmenopausal women. By inhibiting the aromatase enzyme, Aromasin effectively reduces estrogen production, which is essential for the growth of certain types of breast cancer cells. This reduction in estrogen levels helps slow the progression of the disease and decreases the likelihood of recurrence.
The drug works by irreversibly binding to the aromatase enzyme, leading to a permanent inactivation of the enzyme within tumor cells. As a result, the overall estrogen production in the body is significantly lowered. This mechanism makes Aromasin particularly effective in patients whose cancers are driven by estrogen, as it deprives the tumor cells of a critical growth stimulus.
Aromasin is administered orally in tablet form, typically once a day, which offers convenience and ease of use. The dosing regimen is determined based on the patient's overall health, cancer stage, and treatment goals. In many cases, Aromasin is used as adjuvant therapy following surgery or other primary treatments to reduce the risk of cancer recurrence.
While Aromasin is generally well tolerated, it is associated with a range of potential side effects. Common adverse events include hot flashes, joint pain, and fatigue, which are often manageable with supportive care or dose adjustments. In some cases, long-term use may lead to bone density loss, making it important for patients to undergo periodic bone health assessments during therapy.
Overall, Aromasin represents a significant advancement in the hormonal management of breast cancer. By effectively lowering estrogen levels, it provides a targeted treatment option for postmenopausal women with hormone-sensitive tumors. With proper monitoring and supportive measures, Aromasin can help improve long-term outcomes and quality of life for patients facing breast cancer.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
The drug works by irreversibly binding to the aromatase enzyme, leading to a permanent inactivation of the enzyme within tumor cells. As a result, the overall estrogen production in the body is significantly lowered. This mechanism makes Aromasin particularly effective in patients whose cancers are driven by estrogen, as it deprives the tumor cells of a critical growth stimulus.
Aromasin is administered orally in tablet form, typically once a day, which offers convenience and ease of use. The dosing regimen is determined based on the patient's overall health, cancer stage, and treatment goals. In many cases, Aromasin is used as adjuvant therapy following surgery or other primary treatments to reduce the risk of cancer recurrence.
While Aromasin is generally well tolerated, it is associated with a range of potential side effects. Common adverse events include hot flashes, joint pain, and fatigue, which are often manageable with supportive care or dose adjustments. In some cases, long-term use may lead to bone density loss, making it important for patients to undergo periodic bone health assessments during therapy.
Overall, Aromasin represents a significant advancement in the hormonal management of breast cancer. By effectively lowering estrogen levels, it provides a targeted treatment option for postmenopausal women with hormone-sensitive tumors. With proper monitoring and supportive measures, Aromasin can help improve long-term outcomes and quality of life for patients facing breast cancer.
NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.
Aromasin
EXEMESTANE
Generic: EXEMESTANE
EXEMESTANE
Generic: EXEMESTANE
25mg
30 TAB
30 TAB
$29.64